{
  "symbol": "VRAX",
  "company_name": "Virax Biolabs Group Limited",
  "ir_website": "https://ir.viraxbiolabs.com/",
  "structured_data": [
    {
      "section_name": "Latest News",
      "links": [
        {
          "title": "Virax Biolabs Announces Distribution Agreement with Europa Biosite to Commercialize ImmuneSelect in the United Kingdom and Ireland",
          "url": "https://ir.viraxbiolabs.com/news-events/press-releases/detail/65/virax-biolabs-announces-distribution-agreement-with-europa",
          "content": "[ ![](https://d1io3yog0oux5.cloudfront.net/_c6c7d908aa11626a51f50c9b95d5cf0f/viraxbiolabs/files/theme/site-files/20241030/viraxbiolabs.com/wp-content/uploads/2024/04/virax-biolabs-logo.png) ](https://www.viraxbiolabs.com)\n\nMenu\n\n[ ![](https://d1io3yog0oux5.cloudfront.net/_c6c7d908aa11626a51f50c9b95d5cf0f/viraxbiolabs/files/theme/site-files/20241030/viraxbiolabs.com/wp-content/uploads/2024/04/virax-biolabs-logo.png) ](https://www.viraxbiolabs.com)\n\nMenu\n\n# Press Releases\n\n# Virax Biolabs Announces Distribution Agreement with Europa Biosite to Commercialize ImmuneSelect in the United Kingdom and Ireland\n\nOctober 23, 2024 7:30am EDT  [ Download as PDF ](https://d1io3yog0oux5.cloudfront.net/_c6c7d908aa11626a51f50c9b95d5cf0f/viraxbiolabs/news/2024-10-23_Virax_Biolabs_Announces_Distribution_Agreement_65.pdf \"PDF: Virax Biolabs Announces Distribution Agreement with Europa Biosite to Commercialize ImmuneSelect in the United Kingdom and Ireland\")\n\nLONDON, Oct. 23, 2024 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) (\"Virax\" or the \"Company\"), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, today announced that it has entered into a distribution agreement with Europa Biosite to commercialize the company's ImmuneSelect Research Use portfolio in the United Kingdom and Ireland through its wholly owned subsidiary Cambridge Bioscience.\n\n[ ![\\(PRNewsfoto/Virax Biolabs\\)](https://mma.prnewswire.com/media/1879039/Virax_Biolabs_Logo_Logo.jpg) ](https://mma.prnewswire.com/media/1879039/Virax_Biolabs_Logo_Logo.html \"Opens in a new window\")\n\n\"ImmuneSelect is an important suite of profiling solutions for assessing adaptive immunity and we are pleased to partner with Europa Biosite, a leader in life science distribution across Europe,\" said **James Foster, CEO of Virax Biolabs.** \"We believe this partnership will meaningfully expand our commercial footprint in the UK and Ireland and make ImmuneSelect accessible to researchers and pharmaceutical companies as they work to better understand the role of T cell response and immune status.\"\n\n\"We are happy to partner with innovative companies like Virax Biolabs,\" commented **Martijn Blommaart, Director of Supplier Development at Europa Biosite.** \"We look forward to leveraging our commercial infrastructure to quickly deliver and provide local technical support to ensure that ImmuneSelect is available in the UK & Ireland\"\n\n**About ImmuneSelect**\n\nImmuneSelect is the Company's portfolio of research products dedicated to investigating adaptive immunity. Products within the ImmuneSelect brand are for research and investigational use only and are not intended to be used as a diagnostics tool. The ImmuneSelect portfolio includes peptide pools covering epitopes from pathogens, optimized for the stimulation of T cells. The initial offerings include pools for SARS-CoV-2, SARS-CoV-2 MHC-1 (\"CD8\"), Lyme Disease, Cytomegalovirus (\"CMV\"), Respiratory Syncytial Virus (\"RSV\") and Epstein-Barr Virus (\"EBV\"), which continue to be regularly expanded. ImmuneSelect's Recombinant Antibodies target cytokines and biomarkers, and they are available in different versions unconjugated to be tested on a range of applications including Flow Cytometry, ELISA and ELISpot/Fluorospot. ImmuneSelect is affordable, easy to use, and is compatible with most standard laboratory equipment. \n\n**About Europa Biosite**\n\nEuropa Biosite is a European supplier of life science products and services, composed of six leading distribution companies: Biomol in Germany, Cambridge Bioscience in the UK and Ireland, LubioScience in Switzerland, Nordic Biosite in the Nordics and Baltics, Sanbio in Benelux and Szabo-Scandic in Austria. The group has a portfolio of over 5 million products, representation in 16 European countries and a highly skilled team of over 150 employees. Europa Biosite is the optimal gateway into the European life science market, maximising sales growth through locally tailored solutions and close supply partnerships.For more information, please visit <https://www.europabiosite.com/>.\n\n**About Virax Biolabs Group Limited**\n\nVirax Biolabs Group Limited is an innovative biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Virax Biolabs Group Limited is currently developing T-Cell-based test technologies with the intention of providing an immunology profiling platform. T-Cell testing can be particularly effective in the diagnosis and therapeutics of post-viral syndromes such as Long COVID and other chronic conditions linked to immune dysregulation.\n\nFor more information, please visit [www.viraxbiolabs.com](http://www.viraxbiolabs.com/ \"Opens in a new window\").\n\n**Investor Relations Contact:** Russo Partners, LLC Nic Johnson 12 West 27th Street 4th Floor New York, NY 10001 M: 303-482-6405 nic.johnson@russopartnersllc.com\n\nView original content to download multimedia:<https://www.prnewswire.com/news-releases/virax-biolabs-announces-distribution-agreement-with-europa-biosite-to-commercialize-immuneselect-in-the-united-kingdom-and-ireland-302283521.html>\n\nSOURCE Virax Biolabs\n\nReleased October 23, 2024\n\n  * [Email Alerts](/news-events/email-alerts)\n  * [Contacts](/company-information/contacts)\n  * [RSS News Feed](https://ir.viraxbiolabs.com/news-events/press-releases/rss \"Opens in a new window\")\n\n\n\nHi! Could we please enable some additional services for **Analytics, Marketing, Functionality, Strictly Necessary & Security**? You can always change or withdraw your consent later.\n\n[Let me choose...](#)\n\nI declineThat's ok\n\nNotifications\n"
        },
        {
          "title": "Virax Biolabs Announces Extension of Existing Exclusive Distribution Agreement to Market Mpox (formerly Monkeypox) Virus Real-Time PCR Detection Kits with Cosmos Health Inc.",
          "url": "https://ir.viraxbiolabs.com/news-events/press-releases/detail/64/virax-biolabs-announces-extension-of-existing-exclusive-distribution-agreement-to-market-mpox-formerly-monkeypox-virus-real-time-pcr-detection-kits-with-cosmos-health-inc",
          "content": "**Your web browser (Chrome 91) has a serious security vulnerability!** Update your browser for more security, speed and the best experience on this site. [Update browser](https://browser-update.org/update-browser.html#3.3.55:ir.viraxbiolabs.com) Ignore\n\n[ ![](https://d1io3yog0oux5.cloudfront.net/_c6c7d908aa11626a51f50c9b95d5cf0f/viraxbiolabs/files/theme/site-files/20241030/viraxbiolabs.com/wp-content/uploads/2024/04/virax-biolabs-logo.png) ](https://www.viraxbiolabs.com)\n\nMenu\n\n# Press Releases\n\n# Virax Biolabs Announces Extension of Existing Exclusive Distribution Agreement to Market Mpox (formerly Monkeypox) Virus Real-Time PCR Detection Kits with Cosmos Health Inc.\n\nSeptember 16, 2024 8:30am EDT  [ Download as PDF ](https://d1io3yog0oux5.cloudfront.net/_c6c7d908aa11626a51f50c9b95d5cf0f/viraxbiolabs/news/2024-09-16_Virax_Biolabs_Announces_Extension_of_Existing_64.pdf \"PDF: Virax Biolabs Announces Extension of Existing Exclusive Distribution Agreement to Market Mpox \\(formerly Monkeypox\\) Virus Real-Time PCR Detection Kits with Cosmos Health Inc.\")\n\nLONDON, Sept. 16, 2024 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) (\"Virax\" or the \"Company\"), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, today announced that it has entered into an extension of its already existing exclusive distribution agreement with Cosmos Health Inc. (Nasdaq: COSM) (\"Cosmos\") to commercialize Mpox Virus Real-Time PCR Detection Kits in countries in the Gulf Cooperation Council (\"GCC\"). It had previously signed an agreement for exclusive distribution in Greece & Cyrprus and non-exclusive distribution throughout Europe.\n\n[ ![\\(PRNewsfoto/Virax Biolabs\\)](https://mma.prnewswire.com/media/1879039/Virax_Biolabs_Logo_Logo.jpg) ](https://mma.prnewswire.com/media/1879039/Virax_Biolabs_Logo_Logo.html \"Opens in a new window\")\n\nThe RT PCR Mpox virus detection kits are CE-marked for sale in Europe and also authorized by the Medicines and Healthcare products Regulatory Agency (MHRA), the product regulatory agency for the United Kingdom. These tests perform with a sensitivity of 96.7% and specificity of 93.72%, with the ability to deliver results in under 70 minutes.\n\n\"We are excited to strengthen our partnership with Cosmos. This exclusive agreement expands our geographic reach, providing a wider network of healthcare professionals with essential tools to diagnose and manage the spread of the Mpox virus,\" **James Foster, CEO of Virax Biolabs.** \"We look forward to working closely with Cosmos and leveraging its impressive distribution infrastructure.\"\n\n\"We are happy to further partner with Virax Biolabs as the Company works diligently to mitigate the spread of Mpox and other infectious diseases,\" **commented Greg Siokas, Chief Executive Officer of Cosmos.** \"We continue to see strong demand for Mpox virus detection kits, and we believe that we are well positioned to support Virax and territories in need.\"\n\nUnder the terms of the agreement, Cosmos is authorized to import, sell and distribute Virax-branded Mpox virus Nucleic Acid Detection Kits in the GCC including Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates.\n\n**About Virax Biolabs Group Limited**\n\nVirax Biolabs Group Limited is an innovative biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Virax Biolabs Group Limited is currently developing T-Cell-based test technologies with the intention of providing an immunology profiling platform. T-Cell testing can be particularly effective in the diagnosis and therapeutics of post-viral syndromes such as Long COVID and other chronic conditions linked to immune dysregulation.\n\nFor more information, please visit [www.viraxbiolabs.com](http://www.viraxbiolabs.com/ \"Opens in a new window\").\n\n**About Cosmos Health Inc.**\n\nCosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe® and C-Sept®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at [www.cosmoshealthinc.com](https://pr.report/1rqj \"Opens in a new window\"), [www.skypremiumlife.com](https://pr.report/1rqk \"Opens in a new window\"), [www.zipdoctor.co](https://pr.report/1rqm \"Opens in a new window\"), as well as [LinkedIn](https://pr.report/1rqn \"Opens in a new window\") and [X](https://pr.report/1rqo \"Opens in a new window\").\n\n**Investor Relations Contact:** Russo Partners, LLC Nic Johnson and Adanna G. Alexander, Ph.D. M: 303-482-6405 nic.johnson@russopartnersllc.com\n\nView original content to download multimedia:<https://www.prnewswire.com/news-releases/virax-biolabs-announces-extension-of-existing-exclusive-distribution-agreement-to-market-mpox-formerly-monkeypox-virus-real-time-pcr-detection-kits-with-cosmos-health-inc-302248980.html>\n\nSOURCE Virax Biolabs\n\nReleased September 16, 2024\n\n  * [Email Alerts](/news-events/email-alerts)\n  * [Contacts](/company-information/contacts)\n  * [RSS News Feed](https://ir.viraxbiolabs.com/news-events/press-releases/rss \"Opens in a new window\")\n\n\n\nHi! Could we please enable some additional services for **Analytics, Marketing, Functionality, Strictly Necessary & Security**? You can always change or withdraw your consent later.\n\n[Let me choose...](#)\n\nI declineThat's ok\n\nNotifications\n"
        },
        {
          "title": "Virax Biolabs Presents at H.C. Wainwright's 26th Annual Global Investment Conference",
          "url": "https://ir.viraxbiolabs.com/news-events/press-releases/detail/63/virax-biolabs-presents-at-h-c-wainwrights-26th-annual-global-investment-conference",
          "content": "**Your web browser (Chrome 91) has a serious security vulnerability!** Update your browser for more security, speed and the best experience on this site. [Update browser](https://browser-update.org/update-browser.html#3.3.55:ir.viraxbiolabs.com) Ignore\n\n[ ![](https://d1io3yog0oux5.cloudfront.net/_c6c7d908aa11626a51f50c9b95d5cf0f/viraxbiolabs/files/theme/site-files/20241030/viraxbiolabs.com/wp-content/uploads/2024/04/virax-biolabs-logo.png) ](https://www.viraxbiolabs.com)\n\nMenu\n\n# Press Releases\n\n# Virax Biolabs Presents at H.C. Wainwright's 26th Annual Global Investment Conference\n\nSeptember 09, 2024 8:00am EDT  [ Download as PDF ](https://d1io3yog0oux5.cloudfront.net/_c6c7d908aa11626a51f50c9b95d5cf0f/viraxbiolabs/news/2024-09-09_Virax_Biolabs_Presents_at_H_C_Wainwright_s_26th_63.pdf \"PDF: Virax Biolabs Presents at H.C. Wainwright's 26th Annual Global Investment Conference\")\n\nLONDON, Sept. 9, 2024 /PRNewswire/ -- Virax Biolabs (\"Virax\" or the \"Company\") (NASDAQ: VRAX), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, today announced that Chief Operating Officer, Dr Nigel McCracken is presenting at H.C. Wainwright's 26th Annual Global Investment Conference, held in New York, NY and that the pre-recorded and on-demand presentation is now available.\n\n[ ![\\(PRNewsfoto/Virax Biolabs\\)](https://mma.prnewswire.com/media/1879039/Virax_Biolabs_Logo_Logo.jpg) ](https://mma.prnewswire.com/media/1879039/Virax_Biolabs_Logo_Logo.html \"Opens in a new window\")\n\nSession details are as follows:\n\nDate: September 9-11, 2024 at Lotte New York Palace Hotel, New York, NYTitle: Virax BioLabs Company PresentationVirax Participant: Dr Nigel McCracken, Chief Operating OfficerPresentation Link: [https://ir.viraxbiolabs.com](https://ir.viraxbiolabs.com/ \"Opens in a new window\")\n\nVirax management will be available during the conference for one-on-one meetings. Interested parties may request a one-on-one meeting.\n\n**About Virax Biolabs Group Limited**\n\nVirax Biolabs Group Limited is an innovative biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Virax Biolabs Group Limited is currently developing T-Cell-based test technologies with the intention of providing an immunology profiling platform. T-Cell testing can be particularly effective in the diagnosis and therapeutics of post-acute infection syndromes such as Long COVID and other chronic conditions linked to immune dysregulation.\n\nFor more information, please visit [www.viraxbiolabs.com](http://www.viraxbiolabs.com/ \"Opens in a new window\").\n\n**Investor Relations Contact:** Russo Partners, LLC Nic Johnson and Adanna G. Alexander, Ph.D. M: 303-482-6405 nic.johnson@russopartnersllc.com\n\nView original content to download multimedia:<https://www.prnewswire.com/news-releases/virax-biolabs-presents-at-hc-wainwrights-26th-annual-global-investment-conference-302241974.html>\n\nSOURCE Virax Biolabs\n\nReleased September 9, 2024\n\n  * [Email Alerts](/news-events/email-alerts)\n  * [Contacts](/company-information/contacts)\n  * [RSS News Feed](https://ir.viraxbiolabs.com/news-events/press-releases/rss \"Opens in a new window\")\n\n\n\nHi! Could we please enable some additional services for **Analytics, Marketing, Functionality, Strictly Necessary & Security**? You can always change or withdraw your consent later.\n\n[Let me choose...](#)\n\nI declineThat's ok\n\nNotifications\n"
        }
      ]
    },
    {
      "section_name": "Investor Presentation",
      "links": [
        {
          "title": "View Presentation",
          "url": "https://d1io3yog0oux5.cloudfront.net/_c6c7d908aa11626a51f50c9b95d5cf0f/viraxbiolabs/db/2309/21641/pdf/%5BCORRECTED%5D+HC+Wainright+conference+-+Virax+Biolabs+presentation+09+Sept+24l.pdf",
          "content": "DEVELOPING DIAGNOSTICS FOR IMMUNE PROFILING IN INDICATIONS ASSOCIATED\nWITH CHRONIC INFLAMATION AND T-CELL EXHAUSTION\nForward Looking Statements\nFORWARD-LOOKING STATEMENTS\nThis document contains forward-looking statements, about our Forward-looking statements relate to anticipated or expected events,\nexpectations, beliefs or intentions regarding, among other things, activities, trends or results as of the date they are made. Because\nour product development efforts, business, financial condition, forward-looking statements relate to matters that have not yet\nresults of operations, strategies or prospects. In addition, from time occurred, these statements are inherently subject to risks and\nto time, we or our representatives have made or may make uncertainties that could cause our actual results to differ materially\nforward-looking statements, orally or in writing. Forward-looking from any future results expressed or implied by the forward-looking\nstatements can be identified by the use of forward-looking words statements. Many factors could cause our actual activities or results\nsuch as “believe,” “expect,” “intend,” “plan,” “may,” “should” or to differ materially from the activities and results anticipated in\n“anticipate” or their negatives or other variations of these words or forward-looking statements, including, but not limited to, the factors\nother comparable words or by the fact that these statements do summarized below.\nnot relate strictly to historical or current matters. These forward-\nCopyright of all published material, including photographs, drawings\nlooking statements may be included in, but are not limited to,\nand images in this presentation remain with Virax Biolabs and\nvarious filings made by us with the U.S. Securities and Exchange\nrelevant third parties, as appropriate. Consequently, no reproduction\nCommission, or the SEC, press releases or oral statements made by\nin any form of the presentation, or parts thereof, is permitted without\nor with the approval of one of our authorized executive officers.\nthe prior written permission, and only with appropriate\nacknowledgements.\nVirax Biolabs Strategy\n• Virax Biolabs is looking to bring to the market a comprehensive set of T-Cell Diagnostics and Immune\nProfiling Solutions utilizing its novel ViraxImmune platform\n• Initial launch of ImmuneSelect profiling solutions and T-Cell assays for researchers and drug companies\n• Strategic focus on the development and commercialization of immune profiling IVDs for the monitoring\nof T Cells as well as in indications associated with chronic inflammation and immune dysfunction\n• Post-acute infection syndromes (Long COVID, CMV, RSV, ME/CFS, etc.)\n• Assessment of protective immunity (Lyme Disease infection and post transplant infection)\n• Immuno-oncology (CAR T-Cell)\n• Global in vitro diagnostic (IVD) market estimated to be worth approximately $100 Billion\nImmuneSelect – Portfolio of products for Research\nT-cell activation Immune profiling Antibody solutions Laboratory services\nPeptide pools ELISpot/FluoroSpot kits Recombinant antibodies Ab development services\nFluoroSpot Selector Flow cytometry panels Custom peptide synthesis\n• Increasing catalogue of infectious • Unconjugated or labelled, for different • Antibodies sequencing and re-\ndiseases (currently 8 products • ELISpot available in multiple format application (FACS, ELISA, WB…) with a engineering options\navailable) • Capability to monitor multiple focus on cytokines and cell markers • Discovery from phage library\n• Designed for immune response aspect of the immune response • FC panels targeting Human T-cell and • Bioconjugation of proteins\nimmune checkpoints • Peptide design for complete protein\nprofiling\n• 5 panels available at launch sequence or selected epitopes\nCommercialization Targeting\n• CLIA laboratories in US • Researchers\n• International distributors • Drug Companies\n• Dedicated sales network • Clinical Research\n4\nViraxImmuneTM IVD Platform Pipeline\nIVD performance\nIndication Feasibility Development Commercialization\nstudies\nPost-acute Infection\nSyndromes (long COVID,\nME, PTLDS, Tropical)\nProtective immunity\n(Transplant)\nProtective immunity\n(Lyme Disease)\nCAR-T Therapy\nViraxImmuneTM –Post-Acute Infection Syndromes (PAISs) IVD\nNo reliable diagnosis available\nNeed Opportunity\nViraxImmuneTM IVD test technology\n• Current methods based on questionnaire and\nexclusion of other diseases.\n• Only few specialists of those chronic conditions\n• Detection of multiple antibodies coupled to • No reliable diagnosis available • Reduced time to diagnosis\nspecific immune response and surface markers\n• More accurate with less false positive than ELISA-\n• Complex patient journey • Early treatment management\nbased assays\nComplex Patient Journey ~ 6 to 18 months\n~ 6 to 18 months\n1.Initial symptoms and primary care • Reduced medical spend and loss of\n• Patients experience persistent symptoms\n• Long lasting symptoms (years) earnings\n• Multiple visits to PCP with inconclusive results.\n2.Fragmented care\n• Referral to various specialists (e.g., infectious\n• 50-80% reduction clinical evaluation and\ndisease, neurology, rheumatology).\n• Extensive wait times for appointments. assessments\n• Multiple diagnostic tests (blood work, imaging, etc.). • Reduced time before patients re-enters\nworkforce\nMajor Burden on US economy\n(2% of population)\n• Opportunity to develop multiple IVDs\nOutput\n• $528 billionB iunrcdreena osne U iSn emcoendoimcayl for post-acute infection syndromes\n(long COVid, ME/CFS, PTLDS)\n• Confirmation of T cell dysfunction linked to spend ($11,000/person)\nsymptoms associated with post-acute infection • $928 billion loss of earnings\nsyndrome\n6\nViraxImmuneTM –Protective Immunity IVD\nManagement of Post-Transplant patients\nViraxImmune Immune assessment IVD\nNeed Opportunity\nUnique detection method based on improved ELISpot\ntechnology\n• Provide non-invasive,\n• Virus reactivation following\n• Cheap strip-based assay\naccurate predictor of AR\n• Detection of antibodies coupled to specific immune therapeutic immuno-\ndue to virus reactivation\nresponse suppression is a major cause of\n• More accurate with less false positive than ELISA- Acute Organ Rejection (AR)\nbased assays • Diagnostic covering\nmultiple viruses to guide\n• Biopsy remains the gold\ntherapeutic intervention\nstandard for the diagnosis of AR\nDetection of Lyme Disease\nNeed Opportunity\n• Current diagnostics not adequate • Accuracy increased to 95% +\nOutputs\n• Lack of sensitivity\n• No guidance around cure • Guidance on effectiveness of\n• Confirmation of an existing infection\n• If the immune system has successfully cleared the antibiotic treatment\npathogen off the body • Bacteria sometimes survive\n• Provide information on the infection stage (early antibiotic treatment leading to • Detection of infection years\ninfection/late)\nPost-treatment Lyme disease after the tick bite\nsyndrome (PTLDS)\n7\nViraxImmuneTM –Large Addressable Market for IVDs\nPOTENTIAL MARKET SIZE IN US POTENTIAL MARKET SIZE IN EUROPE\nManagement of post-transplant patients\n8\nViraxImmuneTM – Key Milestones\n2023 2024 2025 2026\nLaunch of ImmuneSelect product range\n✓ ISO9001:2015 QMS and ISO13485:2016 FDA application for protective\nfor research:\nMedical Devices certifications immunity IVD product\n• ELISpot kits for infectious disease\n✓Opening R&D and manufacturing • Peptide pools\nInitiation of clinical performance\nsite in Glasgow, UK\nCollection of Long-Covid clinical Commercialisation of ViraxImmune study for post-acute infection\n✓\nsamples (3 clinical collaborations) reader instrument syndromes IVD product\nViraxImmune CAR-T IVD\nInitiation of market access and\n✓ ImmuneSelect commercialization: Development completed\npricing discussions\n• FluoroSpot Selector\n✓Early-Access Program for\n• Flow cytometry panels for T-cell\nSARS-CoV-2 ELISpot ✓ Initiation of post-acute infection studies\nsyndrome (PAIS) clinical study\nInitiation of clinical performance\nAgreement with leading distributer of\nstudy for protective immunity IVD\nresearch products\nproduct\nImmuneSelect commercialization:\n• Recombinant antibodies solutions\nFDA Pre-Submission Lyme disease\n• FluoroSpot kits\nFDA Pre-Submission to discuss\nPAIS and transplant IVDs\n9\nFinancial and Investment Highlights\nFINANCIAL AND INVESTMENT HIGHLIGHTS\nNo Debt Strong Working Capital Poised for Strong Profitable Growth\nMarket Cap at August 23, 2024 $23.4 million Shares Outstanding 4,341,956\nCash runway\nCash at March 31, 2024 $3.6 million\nand working\nWarrants Outstanding 1,355,911 at $3.13\nFunds Raised since March 2024 $6.0 million capital\nexpected to be\nenough to get Options Outstanding 452,000 at $12.67\nWorking Capital at March 31, 2024 $4.2 million through key\nmilestones and\nWorking Capital (as adjusted) $10.2 million\nlaunch of IVD 4,446,305\nAvg. daily trading volume (90 day)\nshares/day\nExpected Avg. monthly burn rate $230,000 products\nShare price range (90 day) $0.79 - $9.00\nRUO sales expected to exceed R&D costs in 2024\n10\nVirax BioLabs Leadership Team\nVirax Biolabs Leadership Team\nJAMES FOSTER Dr NIGEL McCRACKEN\nJASON DAVIS\nChief Executive Officer\nChief Operations Officer\nChief Financial Officer\nOUR OFFICES\nGlasgow, UK\nInnovation and R&D\nYAIR EREZ NELSON HAIGHT\nHouston, TX EVAN NORTON\nIndependent Director\nUnited States Independent Director Independent Director\nOffice\nSummary Highlights\nSUMMARY HIGHLIGHTS\nUNPARALLELED PRODUCT OFFERING\nWith the growing population health burdens caused by chronic inflammation\nand T-Cell exhaustion including Post Acute Infection Syndromes,\nViraxImmune has the potential to provide powerful diagnostics that\nfacilitate and empower both the development of robust treatments and the\nresilience of healthcare systems.\nREVENUE STREAMS AND NEAR TERM GO TO MARKET STRATEGY\nLaunch and commercialization of ImmuneSelect profiling solutions and T-Cell\nassays for researchers, clinicians and drug companies working in the areas of\nchronic inflammation, T-Cell exhaustion and protective immunity\nFINANCIAL STABILITY\nWe believe we are well capitalized for the launch of the ViraxImmune\nproduct range.\nThank you for your attention!\nFor further information at please visit\nwww.viraxbiolabs.com"
        }
      ]
    }
  ]
}